Mach7 Technologies (ASX:M7T) FY26 Results to Test AI-Ready Imaging Strategy

Aditi Sarkar

17 August 2026 12:06 PM AEST

Mach7 Technologies (ASX:M7T) FY26 Results to Test AI-Ready Imaging Strategy

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Mach7 Technologies (ASX:M7T) is expected to release FY26 full-year results after guiding to Revenue around 15 per cent below FY25.
The company recorded three consecutive quarters of positive Operating Cash Flow and ended FY26 with A$19.9 million in cash and no debt.
Annualised Recurring Revenue reached A$23.5 million at 30 June 2026, up 7.6 per cent in constant currency.
eUnity diagnostic viewer was listed on Epic's Connection Hub, creating access to healthcare providers using Epic's electronic health record platform.

Mach7 Technologies (ASX:M7T) enters its FY26 reporting season with investors assessing whether a year of revenue pressure has created a stronger operating foundation. The Melbourne-based medical imaging software company has faced lower Capital deal conversion, but it has maintained positive operating cash flow, a debt-free Balance Sheet and growth in annual recurring revenue. The upcoming full-year results will provide insight into whether its AI-ready imaging platform strategy can translate into a more consistent commercial trajectory.

Latest Development

Mach7's fourth-quarter FY26 update provided the latest operational reference point ahead of audited results. The company reported A$1.1 million of positive operating cash flow during the quarter, marking its third consecutive positive period. Cash ended the year at A$19.9 million with no debt, increasing 4 per cent from the March quarter.

Annualised recurring revenue stood at A$23.5 million at 30 June 2026, representing 7.6 per cent growth in constant currency compared with the prior year. Contracted annual recurring revenue was A$25.5 million, consisting of A$23.5 million from live customers and A$2.0 million from Backlog awaiting first productive use.

Mach7 also confirmed that its eUnity diagnostic viewer had been listed on Epic's Connection Hub, providing a potential distribution pathway to healthcare providers using Epic electronic health record systems.

What the Numbers Show

Mach7's FY26 performance represents a shift from the growth recorded in FY25. In FY25, revenue increased 16 per cent to A$33.8 million, while recurring revenue rose 20 per cent to A$25.3 million, representing 75 per cent of total revenue. The company reduced its net loss to A$6.2 million from A$8.0 million and recorded positive NPATA of A$0.4 million.

For FY26, management guided to revenue approximately 15 per cent below FY25 levels, citing delayed conversion of larger capital deals in Asia and the Middle East and customer losses. Operating expenses were expected to be around 10 per cent lower.

The result highlights the difference between recurring subscription revenue and project-based capital revenue. While recurring revenue has continued to grow, contracted annual recurring revenue declined 8.9 per cent year-on-year, reflecting pressure on future contracted income visibility.

Why It Matters

Enterprise medical imaging software operates in a market where customer relationships can last for many years due to the complexity of replacing imaging archives, diagnostic viewers and clinical workflows. This creates a stable recurring revenue opportunity but also makes customer Acquisition and retention important.

Mach7's FY26 performance demonstrates the transition from project-based revenue toward subscription-style income. Annual recurring revenue growth despite lower overall revenue supports the company's strategy of increasing predictable income streams.

The AI opportunity is also central to the company's positioning. Rather than developing its own diagnostic algorithms, Mach7 is positioning its platform as infrastructure that allows healthcare providers to integrate third-party AI tools into existing imaging workflows.

Growth Catalysts

The key growth opportunity is the expansion of Mach7's AI-ready imaging platform. Management has positioned eUnity and its imaging archive technology as the infrastructure layer that allows hospitals to use their own data with external AI applications.

The Epic Connection Hub listing provides another potential distribution channel, while digital pathology capabilities demonstrated at SIIM26 broaden the platform opportunity. The eUnity viewer's integration with AWS HealthImaging also supports cloud-based deployment options.

Commercial wins including UnityPoint Health converting a legacy capital customer to subscription and the five-year AMRADNET agreement provide examples of the company's subscription and contract expansion strategy. Continued conversion of healthcare customers toward recurring contracts remains the main commercial objective.

Risks Investors Should Watch

The primary risk is revenue volatility. Mach7 continues to rely partly on large capital deals, and delays in customer decisions can materially affect reported revenue. The FY26 revenue decline demonstrates this sensitivity.

The decline in contracted annual recurring revenue is another Factor to monitor because it affects future revenue visibility. Competition from larger healthcare technology companies remains significant, while digital pathology capabilities are still limited to reference and referral use in the United States rather than primary diagnosis.

Leadership changes also remain a consideration, with Shawni Craddock serving as interim chief financial officer. With a relatively modest market capitalisation, any weaker-than-expected FY27 outlook could affect investor sentiment.

What Happens Next

The FY26 audited results will be the next key milestone. Investors will focus on whether recurring revenue growth has continued, whether cash flow remains positive and how the contracted backlog is positioned entering FY27.

The market will also look for further detail on how the AI-ready platform strategy is translating into commercial contracts. With no Debt and approximately A$20 million in cash, Mach7 has financial flexibility, but future valuation will depend on converting technology positioning into measurable Business growth.

Conclusion

Mach7 Technologies (ASX:M7T) enters FY26 results in a transition phase, balancing lower headline revenue with improving recurring revenue quality and cash generation. The company has maintained a debt-free balance sheet, increased annual recurring revenue and expanded its AI-ready imaging platform capabilities. However, the decline in contracted annual recurring revenue and reliance on large capital contracts remain important challenges. The upcoming results and FY27 outlook will determine whether FY26 represents a temporary reset or the beginning of a more sustainable operating model.

FAQs

Q: When will Mach7 Technologies release FY26 results?

A: Mach7 Technologies is expected to release its FY26 full-year results in August 2026.

Q: What was Mach7's annualised recurring revenue at FY26 year-end?

A: Annualised recurring revenue was A$23.5 million at 30 June 2026.

Q: How much cash did Mach7 hold at the end of FY26?

A: Mach7 ended FY26 with A$19.9 million in cash and no debt.

Q: What is Mach7's AI-ready imaging strategy?

A: Mach7 provides imaging infrastructure designed to allow healthcare providers to integrate third-party AI tools into clinical workflows.

Q: What is eUnity?

A: eUnity is Mach7's diagnostic imaging viewer platform used for accessing and reviewing medical images.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.